The Central Social Insurance Medical Council, better known as Chuikyo, appears to see the need to set up new dosage…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Torii Puts Off Launch of Sublingual Hay Fever Drug
April 1, 2014
-
BUSINESS Shionogi Predicts Milder Patent Cliff for Crestor after AZ Deal: Pres.
March 31, 2014
-
BUSINESS Suglat Tops February “Mind Share” Ranking in GP Market
March 31, 2014
-
ORGANIZATION JPMA to Ban Drug Makers from Giving Grants for Clinical Research on Own Products
March 28, 2014
-
ORGANIZATION Funding Disclosures by 5 More FPMAJ Trade Groups to Get Underway in FY2014
March 27, 2014
-
BUSINESS Major Generic Prices to Hover around 50% of Original Drug Prices in Their 1st Revision: Jiho
March 26, 2014
-
BUSINESS Novartis Will Not Sell Rasilamlo Blood Pressure Drug in Japan
March 26, 2014
-
REGULATORY MHLW to Disclose Names of Wholesalers Abusing Penalty for Low Price-Settlement Rates
March 25, 2014
-
ACADEMIA Experts Disagree over Full-Introduction of GCP at JCS Meeting
March 24, 2014
-
ORGANIZATION JPMA Urges Takeda to Improve Promotion Regime over CASE-J
March 24, 2014
-
REGULATORY MHLW to Set Rules on OTC Switching of Diagnostics This Year
March 20, 2014
-
BUSINESS Eli Lilly Japan Sales Up 9% in 2013
March 19, 2014
-
ACADEMIA Trial Investigators Brush Aside Concerns over CASE-J in US Journal
March 18, 2014
-
ACADEMIA University of Tokyo Admits Patient Information on SIGN Trial Leaked to Novartis
March 17, 2014
-
REGULATORY Eligibility for Key Pricing Premium Up for Discussion: Govt
March 17, 2014
-
BUSINESS LEO Pharma to Carefully Ponder When to Begin Solo Marketing in Japan: Local Head
March 14, 2014
-
BUSINESS Otsuka to Disclose Patient-Level Clinical Trial Data
March 13, 2014
-
BUSINESS AstraZeneca, Osaka University Aim to Resurrect Ditched Drug Candidates
March 13, 2014
-
ORGANIZATION PhRMA “Disappointed” by Rule Changes for Foreign Price Adjustments: New Japan Committee Chair
March 12, 2014
-
REGULATORY Revisions of Prefectural Disaster Plans for Drug Distribution Almost Complete
March 11, 2014
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…